Carmat - Implantation momentum
Carmat recently announced that it has implanted nine of its physiologic heart replacement therapies (PHRT) since July, six of which were commercial...
Video: Carmat - executive interview with Stéphane Piat
Carmat is French biotech company that has created the first auto-regulating, bioprosthetic artificial heart able to mimic the natural physiology of...
Carmat - Full-year results and clinical updates
In January, Carmat announced data from the initial 10 patients included in the first leg of its EU pivotal study investigating the surgical...
Carmat - First half of CE mark-enabling trial fully enrolled
In July, Carmat announced the enrolment of the 10th and final patient included in the first leg of its EU pivotal study investigating the surgical...
Carmat - Carmat raises €52.9m and extends cash runway
Carmat raised €52.9m through the sale of 2.645m shares at €20.0 per share. We estimate that this should increase the firm’s cash runway into Q219,...
No more insights